Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESP301 feasibility study in community patients with COPD or bronchiectasis at risk of respiratory viral infection
2020-004951-34Phase 2Unknown
- Sponsor
- Thirty Respiratory Limited
- Start
- Nov 2020
- Modality
- Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of RESP301 in chronic obstructive pulmonary disease (COPD) and bronchiectasis, sponsored by Thirty Respiratory Limited. Primary endpoint: Feasibility of self-administering RESP301 with a nebuliser. Status: unknown.
02
Drugs
RESP301
03
Conditions
chronic obstructive pulmonary disease (COPD)bronchiectasis
Beyond the preview
Go deeper on 2020-004951-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004951-34.